NMDA receptor (NMDAR)-mediated excitotoxicity plays an important role in several CNS disorders, including epilepsy, stroke, and ischemia. Here we demonstrate the involvement of striatal-enriched protein tyrosine phosphatase (STEP) in this critical process. STEP 61 is an alternatively spliced member of the family that is present in postsynaptic terminals. In an apparent paradox, STEP 61 regulates extracellular signal-regulated kinase 1/2 (ERK1/2) and p38, two proteins with opposing functions; activated p38 promotes cell death, whereas activated ERK1/2 promotes cell survival. We found that synaptic stimulation of NMDARs promoted STEP 61 ubiquitination and degradation, concomitant with ERK1/2 activation. In contrast, extrasynaptic stimulation of NMDARs invoked calpain-mediated proteolysis of STEP 61 , producing the truncated cleavage product STEP 33 and activation of p38. The calpain cleavage site on STEP was mapped to the kinase interacting motif, a domain required for substrate binding. As a result, STEP 33 neither interacts with nor dephosphorylates STEP substrates. A synthetic peptide spanning the calpain cleavage site efficiently reduced STEP 61 degradation and attenuated p38 activation and cell death in slice models. Furthermore, this peptide was neuroprotective when neurons were subjected to excitotoxicity or cortical slices were exposed to ischemic conditions. These findings suggest a novel mechanism by which differential NMDAR stimulation regulates STEP 61 to promote either ERK1/2 or p38 activation and identifies calpain cleavage of STEP 61 as a valid target for the development of neuroprotective therapy.
Introduction
Glutamate excitotoxicity is an important component in the etiology of several neurological and neurodegenerative diseases (Lipton and Rosenberg, 1994; Arundine and Tymianski, 2003) . Exposure to high levels of glutamate leads to overactivation of NMDA receptors (NMDARs) and influx of Ca 2ϩ , both of which disrupt normal intracellular signaling and contribute to neuronal cell death (Lipton and Rosenberg, 1994; Lipton, 1999) . Despite the evidence implicating NMDAR activity in cell death, synaptic NMDAR activity is also implicated in neuronal survival and the development of synaptic plasticity (Malenka and Nicoll, 1993; Mabuchi et al., 2001; Xu et al., 2007) . The mechanisms by which NMDAR activation lead to both prosurvival and proapoptotic pathways is an important question in neurobiology.
Recent studies on the differential stimulation of synaptic versus extrasynaptic NMDARs suggest some answers to this issue (Hardingham et al., 2002; Ivanov et al., 2006) . Stimulation of synaptic NMDARs activates the Ras-extracellular signalregulated kinase (ERK)-cAMP response element-binding protein (CREB) pathway and translation of prosurvival proteins, such as BDNF (Hardingham et al., 2002; Vanhoutte and Bading, 2003; Léveillé et al., 2008; Mulholland et al., 2008) . In contrast, activation of extrasynaptic NMDARs invokes proapoptotic proteins and suppression of survival pathways (Hardingham et al., 2002; Ivanov et al., 2006; Léveillé et al., 2008) . Despite these advances, the precise pathways that regulate this process remain essentially unknown.
Striatal-enriched protein tyrosine phosphatase (STEP) is a brain-specific intracellular tyrosine phosphatase that antagonizes activity-dependent strengthening of synapses (Braithwaite et al., 2006) . STEP isoforms are targeted to different intracellular compartments and are derived by alternative mRNA splicing. STEP 46 is a cytosolic variant (Lombroso et al., 1991 (Lombroso et al., , 1993 , whereas STEP 61 is a membrane-associated isoform that localizes to the endoplasmic reticulum and the postsynaptic terminal (Boulanger et al., 1995; Oyama et al., 1995; Bult et al., 1996) . STEP members regulate important synaptic signaling proteins, including two members of the mitogen activated protein kinase (MAPK) family, ERK1/2 and stress-activated protein kinase p38 (Muñoz et al., 2003; Paul et al., 2003) . It also regulates the Src kinase family member Fyn (Nguyen et al., 2002) and the NMDAR subunit NR2B (Snyder et al., 2005) . STEP dephosphorylates ERK1/2, p38, and Fyn kinases at regulatory tyrosine residues within their activation loop, thereby inactivating them. In the case of NR2B, STEP dephosphorylation of Tyr 1472 facilitates in-ternalization of the NR1/NR2B receptor complex (Snyder et al., 2005) . STEP activity also mediates internalization of GluR1/ GluR2-containing AMPA receptors (AMPARs) after activation of group I metabotropic glutamate receptors, although whether this is attributable to a direct dephosphorylation of GluR2 remains to be determined . STEP 61 is a substrate for the Ca 2ϩ -dependent protease calpain and is rapidly cleaved to a smaller isoform (STEP 33 ) after strong glutamatergic stimulation, such as during excitotoxic or ischemic insult Gurd et al., 1999; Braithwaite et al., 2008) . Although calpain-dependent conversion of STEP 61 to STEP 33 has been known to occur, the functional significance of this has not been assessed. Given the importance of STEP 61 in regulating neurotransmission and its susceptibility to excitotoxicity, we evaluated the differential effects of activation of synaptic versus extrasynaptic NMDARs with regard to possible calpainmediated inactivation of STEP 61 and subsequent activation of p38 and cell death pathways. These results implicate the proteolysis of STEP 61 as a potential target for neuroprotection from glutamatergic excitotoxicity.
Materials and Methods
Antibodies and reagents. All antibodies used in this study are listed in Table 1 . Glutamate, MK-801 [(ϩ)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate], ifenprodil, CNQX, NMDA, glycine, D-AP-5, and bicuculline were purchased from Sigma-Aldrich. Calpeptin, ALLN (N-acetyl-Leu-Leu-Nle-CHO), cpm-VAD-CHO, lactacystin, epoximicin, chloroquine, TTX, nifedipine, carbobenzoxy-L-leucyl-Lleucyl-L-leucinal (MG-132) and Suc-LLVY-AMC were from Calbiochem. Cdk5 small interfering RNA (siRNA) was purchased from Santa Cruz Biotechnology (Table 1) .
Recombinant glutathione S-transferase (GST)-STEP 46 , GST-STEP 33 , GST-STEP 46 (C to S), GST-STEP 33 (C to S), and GST were affinity purified as described previously (Nguyen et al., 2002) . Trans-activating transduction (TAT)-STEP 46 and TAT-STEP 33 were purified from Top10 Escherichia coli by using TALON metal beads (Clontech). For inhibition of calpain-mediated cleavage of STEP 61 , TAT-myc peptide and TAT-STEP peptide were synthesized by the Keck Facility at Yale University (New Haven, CT).
Primary neuronal cultures and treatments. The Yale University Institutional Animal Care and Use Committee approved all procedures. Primary cortical neurons were isolated from rat embryonic day 18 embryos as described previously (Hu et al., 2007; Zhang et al., 2008) . Cells were dissociated with trypsin and resuspended in HBSS (in mM): 137.9 NaCl, 5.3 KCl, 0.33 Na 2 HPO 4 , 0.44 KH 2 PO 4 , 4.17 NaHCO 3 , and 5.55 glucose. Cells were plated on poly-D-lysine-coated plates (1 ϫ 10 6 cells per well) in Neurobasal supplemented with 2% B27 (Invitrogen) and grown for 14 -21 d. To stimulate neurons with glutamate, cells were washed with HBSS buffer, and the initial medium was replaced by medium containing 100 M glutamate for the indicated periods of time. In some experiments, inhibitors and antagonists were added to the medium 30 min before and throughout the treatment with glutamate (100 M) for 60 min.
Stimulation of synaptic versus extrasynaptic NMDAR. Synaptic versus extrasynaptic stimulations were performed as described in previously established protocols (Hardingham et al., 2002; Ivanov et al., 2006; Lév-eillé et al., 2008) . Briefly, cortical neurons were plated (7 ϫ 10 4 cells/ cm 2 ) in minimum essential medium (MEM) with 10% Nu serum (BD Biosciences). At days 3, 7, and 13, half of the medium was changed to MEM and 2% B27. Neurons were preincubated in medium containing TTX (1 M), CNQX (40 M), D-AP-5 (100 M), and nifedipine (5 M) for 3 h before stimulation.
For synaptic stimulation, cells were incubated in medium containing bicuculline (10 M), glycine (10 M), and nifedipine (5 M) for 15 min.
For extrasynaptic stimulation, synaptic NMDARs were irreversibly blocked by the addition of MK-801 (50 M) for 5 min under the conditions stated above (10 M bicuculline, 10 M glycine, and 5 M nifedipine). Subsequently, the medium was changed to include TTX (1 M), CNQX (40 M), nifedipine (5 M), NMDA (10 M), and glycine (10 M) for 15 min.
For stimulation of all NMDARs, neurons were incubated in medium containing TTX (1 M), CNQX (40 M), nifedipine (5 M), NMDA (10 M), and glycine (10 M) for 15 min. Immediately after stimulation, neurons were rapidly lysed in radioimmunoprecipitation assay (RIPA) buffer as described previously (Braithwaite et al., 2008) .
Calpain activity assay. Cortical neurons treated with synaptic and extrasynaptic stimulations as described above were used for the calpain activity assay. The same amount of neuron lysates were diluted in assay buffer (50 mM Tris-HCl, pH 7.4, 10 mM CaCl 2 , and 2 mM DTT) in the presence of a fluorogenic calpain substrate Suc-LLVY-AMC (Calbiochem). Cleavage of Suc-LLVY-AMC by calpain to its fluorescent product aminomethylcoumarin (AMC) was used to measure calpain activity as described previously (Meng et al., 1999; Boland and Campbell, 2003) . After 30 min incubation at room temperature, reactions were stopped by the addition of an equal volume of 125 mM sodium borate buffer, pH 9.0, containing 7.5% ethanol. Fluorescence was assessed measuring excitation at 360 nm and emission at 440 nm using a fluorescence plate reader. siRNA transfection. Cdk5 siRNA (Santa Cruz Biotechnology) is a pool of three target-specific 20 -25 nt siRNAs designed to knockdown Cdk5 expression. Final concentrations (80 nM) of siRNAs were transfected into primary cortical neurons at 6 d in vitro (DIV) using Lipofectamine 2000 reagent according to the instructions of the manufacturer. After 6 -8 d of growth in the presence of the siRNAs, neurons were stimulated with synaptic or extrasynaptic protocols and harvested in RIPA buffer.
Slice preparations and treatments. Adult male Sprague Dawley rats (6 -8 weeks; Charles River Laboratories) or male STEP wild-type (WT) and knock-out (KO) mice (8 -10 weeks) were used for all biochemical experiments. Brains were removed and placed in ice-cold oxygenated artificial CSF (aCSF) (in mM): 124 NaCl, 4 KCl, 26 NaHCO 3 , 1.5 CaCl 2 , 1.25 KH 2 PO 4 , 1.5 MgSO 4 , and 10 D-glucose. Coronal corticostriatal slices (300 m) were equilibrated for 60 min in aCSF at 30°C under constant oxygenation with 95% O 2 /5% CO 2 . Slices were transduced with TAT-STEP 46 , TAT-STEP 33 , or TAT-myc (2 M) for 30 min before homogenization and subcellular fractionation. This treatment allows transduction of nearly 100% of cells (Paul et al., 2007) . In some experiments, corticostriatal slices from STEP WT and KO mice were allowed to recover for 60 min before oxygen-glucose deprivation (OGD).
Hippocampal slice recordings. For electrophysiology experiments, slices were prepared and whole-cell recordings obtained as described previously by Proctor et al. (2006) . The TAT-STEP peptide or TAT-myc was added to the internal recording electrode solution at 100 nM. To calculate the ratio of NMDA EPSCs and GABA IPSCs, the neuron was voltage clamped at Ϫ55 mV, and NMDA EPSCs were measured first by increasing the stimulus strength to determine the maximal stimulus input. The stimulus strength was then adjusted to 70 -80% of the maximum. The steady-state amplitude of NMDA EPSCs was measured under this stimulus parameter. Subsequently, the GABA A receptor antagonist (bicuculline) was washed out to reveal the GABA IPSC steady-state amplitude under this identical stimulus parameter.
Subcellular fractionation. Slices were homogenized in TEVP buffer (in mM): 10 Tris, pH 7.4, 5 NaF, 1 Na 3 VO 4 , 1 EDTA, 1 EGTA, and protease inhibitor cocktail (Roche) and processed as described previously (Hu et al., 2007) . In brief, homogenates were centrifuged at 1000 ϫ g for 10 min to form S1 and P1 fractions. The S1 fraction was further centrifuged at 10,000 ϫ g for 15 min to obtain a crude synaptosomal fraction (P2) and supernatant (S2). P2 fractions were subsequently resuspended and lysed in hypo-osmotic TEVP buffer containing 35.6 mM sucrose and centrifuged at 25,000 ϫ g for 20 min to yield the synaptosomal membrane fractions (LP1).
To evaluate the localization of p38 and ERK1/2 in synaptic and extrasynaptic membranes, we performed detergent extraction on P2 fractions using 0.5% Triton X-100 as described previously (Gardoni et al., 2006; Davies et al., 2007; Goebel-Goody et al., 2009 ) to enrich membranes for synaptic and extrasynaptic proteins.
Synaptosomes were prepared from WT and Cdk5 conditional KO (cKO) mice as described previously . In brief, hippocampi and cortex/striatum from adult animals were dissected and homogenized. Synaptosomal preparations were purified via multiple centrifugation steps and sucrose gradients. Sample containing synaptosomal preparation was subjected to SDS-PAGE and immunoblot analysis. Data represent pooled samples from three cKO and WT animals.
Protein extraction of the crude mitochondrial fraction was performed as described previously (Fujimura et al., 1998) with modification. In brief, corticostriatal slices were homogenized in lysis buffer (in mM): 20 HEPES, pH 7.5, 250 sucrose, 10 KCl, 1.5 MgCl 2 , 5 NaF, 1 Na 3 VO 4 , 1 EDTA, 1 EGTA, 1 dithiothreitol, and protease inhibitor cocktail. The homogenates were centrifuged at 800 ϫ g for 10 min at 4°C, and the supernatant was centrifuged at 8000 ϫ g for 20 min. The pellet was solubilized in SDS sample buffer and used as the crude mitochondrial fraction. The supernatant was centrifuged at 100,000 ϫ g for 60 min to obtain the cytosolic fraction.
Oxygen and glucose deprivation. OGD was performed as described previously (Zhou and Baudry, 2006 Assessment of neuronal viability. We used three independent techniques to assess and quantify cell death. We first measured LDH release using a CytoTox assay kit (Promega) following the protocol of the manufacturer. Second, we assessed cell viability by using MAP2 staining as described previously (Carrier et al., 2006) . In brief, cortical neurons were rinsed three times with 0.1 M PBS, pH 7.4, and fixed with 4% paraformaldehyde in PBS. Fixed cultures were blocked with 10% normal goat serum (NGS) and 1% BSA in PBST (0.2% Triton X-100) for 1 h at room temperature. Cultures were incubated overnight with anti-MAP2 antibody in 1% BSA in PBST (0.2% Triton X-100) at 4°C and after washes with HRP-conjugated donkey anti rabbit secondary antibody 1 h at room temperature. MAP2 immunoreactivity was measured by adding 50 M Amplex Red (Invitrogen) in 300 l of reaction buffer (50 mM sodium phosphate buffer, pH 7.4, and 200 M hydrogen peroxide). After 30 min of incubation, 100 l of was transferred to a 96-well plate, and the resorufin absorbance was measured at 565 nm. Third, we assessed cell death during glutamate stimulation in the absence or presence of TAT-STEP peptide by looking at alterations in nuclear morphology using the nucleic acid stain 4Ј,6Ј-diamidino-2-phenylindole (DAPI) (Vector Laboratories). Healthy cells display diffuse staining of the nucleus, whereas injured or dead cells show nuclear morphological changes, such as chromatin condensation, nuclear condensation, and fragmentation (Cummings and Schnellmann, 2004) . At least 250 randomly selected cells were counted for each stimulation condition.
Calpain cleavage of STEP in vitro and protein sequencing. Recombinant GST-STEP 46 fusion protein (100 ng) was digested with constitutively active calpain 1 (Calbiochem) at the indicated concentrations in digestion buffer (in mM): 50 Tris, pH 7.4, 1 DTT, and 5 CaCl 2 at 30°C for 30 min. STEP 46 , contained in its entirety in STEP 61 , was used to circumvent technical difficulty in expression and purification of full-length forms of membrane-associated STEP 61 . After digestion, samples were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membrane (Millipore Corporation), and the band corresponding to STEP 33 was excised and sent to Yale Keck Facility for protein sequencing. In some experiments, TAT-STEP peptide (at specified concentrations) or Cdk5/ p25 (50 ng/l) was added to the reaction.
Precipitation with GST fusion proteins. GST, GST-STEP 46 (C to S), or GST-STEP 33 (C to S) (10 g) was bound to glutathione Sepharose beads (GE Healthcare) for 1 h at 4°C. This catalytic domain mutation (C to S) renders STEP inactive, without affecting its ability to bind to its substrates via the kinase interacting motif (KIM). These mutant STEP isoforms are used as substrate-trapping mutants (Snyder et al., 2005; Paul et al., 2007; Tashev et al., 2009) . Washed beads were incubated with rat brain homogenates (100 g) in RIPA buffer for 2 h, washed, and subjected to SDS-PAGE, followed by immunoblotting.
STEP phosphatase activity. Phospho-p38 dephosphorylation by GST-STEP 46 or GST-STEP 33 was conducted by incubating increasing amounts of GST-STEP 46 or STEP 33 proteins with 10 ng of phospho-p38 (Millipore Corporation) in phosphatase assay buffer (in mM: 25 HEPES, pH 7.3, 5 EDTA, and 10 DTT) at 30°C for 30 min. The reactions were terminated by adding SDS sample buffer, and samples were subjected to SDS-PAGE (10%). The C terminus of the NMDA receptor subunit NR2B, fused to GST (GST-NR2Bc), was purified, and 1 g was phosphorylated by Fyn kinase (50 ng; Millipore Corporation) in kinase buffer (in mM): 50 Tris-HCl, pH 7.4, 0.1 EGTA, 10 MgCl 2 and 500 M ATP. Phosphorylated GST-NR2Bc was incubated with GST-STEP 46 or GST-STEP 33 in phosphatase assay buffer at 30°C for 30 min. To determine the phosphorylation state of pY 1472 NR2B, samples were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted with anti-pY 1472 NR2B antibody. Densitometric quantification was performed using the Genetools program (Syngene).
Immunofluorescence and immunoblotting. Cortical neurons were grown in Neurobasal medium with 2% B27. Cultures were treated with TAT-STEP 46 , TAT-STEP 33 , or TAT-myc (2 M) for 30 min, then rinsed with 0.1 M PBS, and fixed in 4% paraformaldehyde with 4% sucrose. Cells were permeabilized with PBS with 0.2% Triton X-100 and blocked with 10% NGS and 1% BSA for 1 h. Cultures were stained with anti-NR1 and anti-synapsin I antibodies overnight at 4°C and incubated with goat anti-rabbit Alexa Fluor 594 or goat anti-mouse Alexa Flour 488 secondary antibodies (1:600; Invitrogen). Microscopy was performed with a Carl Zeiss Axiovert 2000 microscope with an apotome (Applied Scientific Instruments) using a 100ϫ objective lens. All analyses were performed blind to the stimulation conditions of the culture. NR1 puncta were counted along the proximal 10 m of three or more dendrites per neuron, and 20 neurons were used for quantification per treatment. The data were analyzed with a one-way ANOVA with post hoc Tukey's test.
Immunoblotting was conducted as described previously (Hu et al., 2007; Zhang et al., 2008) . Membranes were washed and incubated in peroxidase-conjugated secondary antibodies (1:5000 -1:10,000; GE Healthcare). Bands were visualized using a Chemiluminescent Substrate kit (Pierce) and captured by a G:BOX with the image program GeneSnap (Syngene). All densitometric quantifications were performed using the Genetools program (Syngene).
Statistical analysis. All experiments were repeated at least three times. Data were expressed as means Ϯ SEM. Statistical significance ( p Ͻ 0.05) was determined by Student's t test. For some experiments, data were analyzed with one-way ANOVA with post hoc Tukey's test or post hoc least significant difference test.
Results
Calpain-cleavage of STEP 61 is NMDAR dependent STEP 61 is cleaved to a smaller isoform (STEP 33 ) after glutamate stimulation of cortical cultures or an ischemic insult to the cortex Nguyen et al., 1999; Braithwaite et al., 2008) . We were interested in determining the functional significance of STEP 61 proteolysis. In an initial experiment, primary cortical neurons (DIV 14) were stimulated with glutamate (100 M) at different time points (Fig. 1 A) . As was observed previously, STEP 33 was produced in response to glutamate in a timedependent manner with marked levels occurring by 30 min (317.4 Ϯ 20.6% of control at 30 min; p Ͻ 0.01), with a concomitant decrease in STEP 61 (68.6 Ϯ 3.0% of control at 30 min; p Ͻ 0.01).
We next determined whether the cleavage of STEP 61 was NMDAR dependent (Fig. 1 B) . Treatment of cortical cultures with the NMDAR antagonist MK-801 30 min before glutamate significantly decreased the production of STEP 33 (28.4 Ϯ 1.2% compared with no inhibitor control, p Ͻ 0.01). Furthermore, the NR2B-specific antagonist ifenprodil similarly attenuated STEP 33 generation in response to glutamate stimulation (31.4 Ϯ 0.8%; p Ͻ 0.01). In contrast, the AMPAR antagonist CNQX failed to block STEP 61 cleavage (98.2 Ϯ 1.3% of no inhibitor control; p Ͼ 0.05). For this analysis, we also compared the generation of STEP 33 to the production of fodrin, a known substrate of calpain (Siman et al., 1984) . Fodrin cleavage was also blocked by MK-801 and ifenprodil (14.0 Ϯ 1.7 and 15.6 Ϯ 2.4%, respectively, of no inhibitor control; p Ͻ 0.01). These results suggested that the cleavage of STEP 61 required activation of NR2B-containing NMDARs.
To confirm that conversion of STEP 61 to STEP 33 was mediated by activated calpain, we assessed the effects of a panel of proteolytic inhibitors (Fig. 1C) . Two different calpain inhibitors, calpeptin and ALLN, blocked the cleavage of STEP 61 (13.7 Ϯ 3.0 and 14.4 Ϯ 1.0% of no inhibitor control; p Ͻ 0.01). However, the pan-caspase inhibitor cpm-VAD-CHO, the proteasome inhibitors lactacystin and epoximicin, and the lyzosome inhibitor chloroquine did not prevent cleavage (95.4 Ϯ 1.6, 96.3 Ϯ 2.1, 92.9 Ϯ 4.0, and 93.3 Ϯ 3.7%, respectively, of no inhibitor control; p Ͼ 0.05). These results suggested that the cleavage of STEP 61 was mediated by calpain.
Activation of extrasynaptic NMDARs leads to STEP cleavage and neuronal cell death
The above experiments were conducted by adding glutamate directly to the medium, thereby activating both synaptic and extrasynaptic NMDARs. However, substantial evidence suggests that these two populations of ionotropic glutamate receptors have dramatically different effects on neuronal activity. In addition, a recent study has shown that STEP 61 is present at both synaptic and extrasynaptic sites (Goebel-Goody et al., 2009 ). Therefore, we used a pharmacological protocol to stimulate synaptic or extrasynaptic receptors (Hardingham et al., 2002; Ivanov et al., 2006) (Fig. 2 A) (Ivanov et al., 2006 ). In contrast, extrasynaptic stimulation, but not synaptic stimulation, led to the phosphorylation of p38 at Thr 180 /Tyr 182 under our stimulation conditions (extrasynaptic, 186.6 Ϯ 10.3%, p Ͻ 0.01; synaptic, 118.1 Ϯ 9.0% of control, p Ͼ 0.05) (Fig. 2 A) .
ERK1/2 and p38 may be preferentially activated after synaptic or extrasynaptic NMDAR stimulation, respectively, because they are differentially expressed in synaptic and extrasynaptic membranes. To address this question, we prepared synaptic and extrasynaptic membranes from cortical tissue using previously established protocols (Gardoni et al., 2006; Davies et al., 2007; GoebelGoody et al., 2009) . We found that the concentration of p38 was significantly greater in extrasynaptic membranes than in synaptic membranes ( p Ͻ 0.05). Although ERK1/2 was expressed in both membrane compartments, it did not significantly differ between synaptic and extrasynaptic membranes (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material). Given that p38 was most enriched extrasynaptically, these findings could provide an explanation for why extrasynaptic stimulation preferentially activates p38.
Transient activation of p38 after synaptic stimulation has been reported (Waxman and Lynch, 2005) . Here we confirmed transient activation of p38 after synaptic stimulation, which gradually decreased to basal levels by 15 min. However, we found no significant cleavage of STEP 61 under these conditions (supplemental Fig.  2A , B, available at www.jneurosci.org as supplemental material). In contrast, extrasynaptic stimulation led to a progressive and significant increase in p-p38 levels that was accompanied by cleavage of STEP 61 to STEP 33 (supplemental Fig. 2C , D, available at www. jneurosci.org as supplemental material). These findings demonstrate that extrasynaptic NMDAR stimulation leads to activation of calpain, cleavage of STEP 61 , and phosphorylation of p38.
STEP 61 regulates the activation state of both p38 and ERK1/2 by dephosphorylating them. We hypothesized that differential inactivation of STEP 61 by synaptic or extrasynaptic NMDARs impairs the ability of STEP to dephosphorylate and inactivate these substrates and could therefore underlie the selective activation of ERK1/2 or p38 pathways. To address this question, we evaluated how synaptic and extrasynaptic stimulation of NMDARs regulates STEP 61 degradation. We found that synaptic NMDAR stimulation caused a significant increase in the ubiquitination of STEP 61 (Fig. 2 B, top) (358.0 Ϯ 10.3% of control; p Ͻ 0.01), whereas extrasynaptic NMDAR stimulation did not alter ubiquitinated STEP 61 levels (83.0 Ϯ 15.6% of control; p Ͼ 0.05). These results suggest that ubiquitination of STEP 61 occurs as a result of synaptic NMDAR stimulation but not extrasynaptic stimulation.
In contrast, extrasynaptic stimulation led to STEP 61 proteolysis and a concomitant production of STEP 33 (230.3 Ϯ 19.1% of control; p Ͻ 0.01), whereas synaptic stimulation did not (118.6 Ϯ 9.3%; p Ͼ 0.05) (Fig. 2 B, middle) . When glutamate was added to the cortical cultures (stimulation of both synaptic and extrasynaptic receptors), both STEP 61 and fodrin were cleaved (Fig. 1 ) (supplemental Fig. 2 E, available at www.jneurosci.org as supplemental material). There was a concomitant decrease in STEP 61 levels after both synaptic and extrasynaptic stimulations (Fig. 2 B,   Figure 2 . Activation of extrasynaptic NMDARs causes STEP 61 cleavage and neuronal death. A, Immunoblot analysis comparing the effects of synaptic or extrasynaptic NMDAR stimulation on the phosphorylation of ERK1/2 and p38. Quantitative analyses for each were normalized to ERK2 and are summarized in the bar graphs (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 4). B, Synaptic stimulation in the presence of proteasome inhibitor MG-132 led to accumulation of STEP 61 -ubiquitin conjugates (top), whereas extrasynaptic stimulation led to production of STEP 33 (middle). Both synaptic and extrasynaptic stimulation of NMDARs led to a decrease in STEP 61 levels (bottom). ERK2 was used to normalize the data (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 4). C, Analysis of excitotoxic cell death of cortical neurons subjected to synaptic or extrasynaptic stimulations. Cytotoxicity was assessed by measurement of LDH release (*p Ͻ 0.01, Student's t test; n ϭ 3). bottom) (synaptic, 79.5 Ϯ 5.7% of control, p Ͻ 0.01; extrasynaptic, 65.3 Ϯ 4.8%, p Ͻ 0.01). Together, these data indicate that synaptic stimulation selectively induces ubiquitination and degradation of STEP 61 , which correlated with the phosphorylation of ERK1/2. In contrast, extrasynaptic stimulation causes calpaindependent cleavage of STEP 61 with concomitant phosphorylation of p38.
NCX-3 is a Na ϩ /Ca 2ϩ exchanger known to be cleaved by calpain under excitotoxic insults (Bano et al., 2005) . Extrasynaptic stimulation, but not synaptic stimulation, led to NCX-3 proteolysis ( p Ͻ 0.01) (supplemental Fig. 2 F, available at www.jneurosci.org as supplemental material). In addition, extrasynaptic NMDAR stimulation significantly increased the cleavage of fodrin, another known calpain substrate ( p Ͻ 0.01) (supplemental Fig. 2E , available at www.jneurosci.org as supplemental material).
We then measured calpain activity in neuronal lysates treated with synaptic or extrasynaptic stimulations using fluorogenic calpain substrate Suc-LLVY-AMC as described (supplemental Methods, available at www.jneurosci.org as supplemental material). We found a significant increase of calpain activity during stimulation of extrasynaptic NMDARs compared with synaptic NMDARs ( p Ͻ 0.01) (supplemental Fig. 2G , available at www. jneurosci.org as supplemental material).
Previous studies have found that extrasynaptic stimulation activates cell death pathways, whereas synaptic stimulation promotes cell survival (Hardingham et al., 2002; Martel et al., 2009) . We therefore assessed cell cytotoxicity after synaptic or extrasynaptic stimulation by measuring release of LDH into the medium (Fig. 2C) . Stimulation of extrasynaptic NMDARs for 15 min led to a significant increase of LDH release (457.6 Ϯ 21.2% of control; p Ͻ 0.01), whereas synaptic stimulation had no significant effect (98.0 Ϯ 8.5% of control; p Ͼ 0.05). Addition of glutamate to the cultures also led to significant release of LDH (492.0 Ϯ 25.9% of control; p Ͻ 0.01). These findings were confirmed by an assay of neuron viability, based on MAP2 immunoreactivity (Brooke et al., 1999; Carrier et al., 2006) . Extrasynaptic stimulation decreased MAP2 immunoreactivity, indicating decreased cell viability (65.8 Ϯ 6.7% of control; p Ͻ 0.01), whereas activation of synaptic NMDARs did not (94.6 Ϯ 7.2% of control; p Ͼ 0.05). Total glutamate treatment of cultures also induced a significant decrease in MAP2 immunoreactivity (63.1 Ϯ 7.2% of control; p Ͻ 0.01). These findings suggested that extrasynaptic stimulation led both to the phosphorylation of p38 and the induction of cell death pathways and raised the possibility that these events might be related to the cleavage of STEP 61 .
Cdk5 enhances calpain-mediated cleavage of STEP
A recent study demonstrated that the neuronal protein kinase Cdk5 facilitated calpain-mediated cleavage of substrates and that calpain activation was impaired in Cdk5 cKO mice ). Therefore, we tested whether Cdk5 enzyme affected STEP cleavage in vitro (Fig. 3A) . Recombinant GST-STEP 46 (100 ng) was digested with calpain 1 (0.025 U) with or without Cdk5/ p25 protein (50 ng/l) under linear conditions, and STEP cleavage was assessed by immunoblotting. In the absence of Cdk5 (Fig.  3A) , limited calpain cleavage of GST-STEP 46 was detectable (89.4 Ϯ 5.0% of control for STEP 46 ; p Ͻ 0.05). In contrast, the addition of Cdk5 significantly decreased STEP 46 levels (37.3 Ϯ 4.2 vs 89.4 Ϯ 5.0%; p Ͻ 0.01) and significantly increased the production of STEP 33 (33.3 Ϯ 4.8 vs 100%; p Ͻ 0.01). These data indicate that Cdk5 contributes to the calpain-mediated cleavage of STEP.
Given these findings and the previous indications that Cdk5 may facilitate calpain-dependent cleavage of neuronal substrates Figure 3 . Regulation of STEP cleavage by Cdk5. A, GST-STEP 46 was digested with calpain 1 in the absence or presence of recombinant Cdk5/p25 proteins (50 ng/l). Immunoreactivity of noncleaved GST-STEP 46 was normalized to control without calpain (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). B, Immunoblot analysis and quantitation of STEP 61 and tubulin loading controls in corticostriatal and hippocampal synaptosomes. Tissues from three animals per genotype were pooled. Ctx, Cortex; Str, striatum; Hip, hippocampus. C, Levels of indicated phosphorylation sites in hippocampal lysates from Cdk5 cKO and WT mice. Phosphorylation sites are normalized to total protein levels (*p Ͻ 0.05, Student's t test; n ϭ 6). D, STEP cleavage and p38 activation in Cdk5 siRNA-transfected cortical neurons. Extrasynaptic stimulation and total glutamate bath-induced STEP cleavage was significantly reduced in Cdk5 siRNA-transfected neurons. Moreover, activation of p38 was significantly blocked in Cdk5 siRNA-transfected neurons during extrasynaptic stimulation as well as total glutamate bath (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). , we examined the effects of Cdk5 loss on STEP 61 levels in adult mouse brain using Cdk5 cKO mice. Immunoblot analysis showed that STEP 61 levels were elevated by 30 and 40% in synaptosomes prepared from the corticostriatum and hippocampus of Cdk5 cKO mice compared with WT littermate controls (Fig. 3B) . Consistent with elevated STEP 61 levels, the phosphorylation at Tyr 1472 of NR2B was also significantly attenuated in Cdk5 cKO mice (Fig. 3C ) (78.0 Ϯ 7.0% of WT mice; p Ͻ 0.05), suggesting an increase in STEP activity. In contrast, pSer 1480 of NR2B was not affected ( p Ͼ 0.05). Together, these results indicated that Cdk5 facilitated calpain-dependent cleavage of STEP 61 in vivo.
To further investigate role of Cdk5 on STEP 61 cleavage, we suppressed endogenous Cdk5 levels in cortical neurons by introducing siRNA molecules specific to Cdk5. After 6 -8 d of growth in the presence of Cdk5 siRNAs, neurons were subjected to synaptic or extrasynaptic NMDAR stimulations. Cdk5 levels were significantly decreased in siRNA-transfected neurons compared with nontransfected controls (55.1 Ϯ 5.3%; p Ͻ 0.01). Inhibition of Cdk5 expression with siRNA blocked calpain activity in response to extrasynaptic stimulation, leading to decreased cleavage of fodrin (data not shown). Immunoblot analysis of STEP 33 showed that STEP 61 cleavage is significantly attenuated in Cdk5 siRNA-transfected neurons during extrasynaptic stimulation (135.1 Ϯ 10.2 vs 244.4 Ϯ 13.9%; p Ͻ 0.01) (Fig. 3D ). In addition, we saw a concomitant decrease of p-p38 levels in Cdk5 siRNAtransfected neurons (177.6 Ϯ 8.8 vs 268.8 Ϯ 14.1%; p Ͻ 0.01) (Fig. 3D) . These results suggest that decreased Cdk5 expression led to a decrease in calpain activation, STEP 61 cleavage, and p38 phosphorylation.
STEP 33 does not interact with STEP substrates
To better characterize the calpain-mediated proteolysis of STEP, in vitro cleavage reactions were conducted. Calpain cleaved recombinant STEP 46 in a dose-dependent manner (0.01 U, 70.3 Ϯ 5.7%; 0.05 U, 22.7 Ϯ 2.9%; 0.1 U, 3.4 Ϯ 2.3% of no calpain control; p Ͻ 0.01) (Fig. 4A ). The STEP 33 band was excised and subjected to N-terminal Edman degradation protein sequencing. This analysis revealed that STEP is predominantly cleaved by calpain between residues Ser 224 and Leu 225 . Interestingly, this cleavage site is located within the KIM domain (Fig. 4 B) , which has been identified as a binding site for STEP substrates.
We therefore tested whether cleavage might disrupt the ability of STEP 33 to associate with STEP substrates. Previous studies have established that a point mutation in the catalytic domain (a cysteine to serine mutation) inactivates STEP and produces a substrate-trapping variant. GST-STEP 46 (C to S) binds to its substrates but does not release them (Paul et al., 2003; Snyder et al., 2005) . To determine whether calpain cleavage of STEP disrupted its ability to associate with its substrates, the C to S mutation was generated in the context of GST-STEP 33 and GST-STEP 46 forms of STEP. These proteins were coupled to glutathione beads and incubated with rat brain homogenates to isolate substrates of STEP 33 versus STEP 46 . Immunoblot analysis revealed that STEP 33 lost the ability to bind to four known substrates of STEP (ERK1/2, p38, Fyn, and NR2B) compared with STEP 46 . As a negative control, neither STEP 33 nor STEP 46 bound to GluR1, which is not thought to be substrate of STEP (Fig. 5A) .
As STEP 33 still contains an active phosphatase domain, it was important to establish whether it was able to dephosphorylate its substrates. To this end, we tested the ability of STEP 33 to dephosphorylate p-p38 (Fig. 5B) or p-NR2B (Fig. 5C ) in vitro. Purified p-p38 was incubated with active GST-STEP 46 or GST-STEP 33 , and samples were probed with p-p38 antibody. GST-STEP 46 dephosphorylated p-p38 efficiently and in a concentrationdependent manner (100 nM, 16.8 Ϯ 3.2%; 500 nM, 1.5 Ϯ 1.2% of control; p Ͻ 0.01), whereas STEP 33 did not (100 nM, 107.8 Ϯ 9.2%; 500 nM, 103.3 Ϯ 5.3% of control; p Ͼ 0.05). A similar result was derived using NR2Bc containing the regulatory pY 1472 that was preparatively phosphorylated by Fyn kinase. As determined using a pY 1472 -specific antibody, GST-STEP 46 showed a concentration-dependent activity toward this substrate (250 nM, 51.4 Ϯ 6.0%; 500 nM, 3.7 Ϯ 3.0% of control; p Ͻ 0.01), whereas STEP 33 was unable to dephosphorylate pY 1472 -NR2Bc (250 nM, 91.6 Ϯ 3.4%; 500 nM, 93.0 Ϯ 2.7% of control; p Ͼ 0.05). These data indicated that STEP 33 was unable to bind to or dephosphorylate p-p38 or pY 1472 -NR2Bc.
STEP 33 prevents NMDAR endocytosis
Given that STEP-dependent dephosphorylation of pY 1472 facilitates internalization of NMDARs (NR1/NR2B), the production of STEP 33 could serve to attenuate this process. To test this hypothesis, several forms of STEP were derived bearing an 11 aa TAT peptide capable of permeabilizing cells. These forms of STEP have been confirmed to transduce into cells with near 100% efficiency (Paul et al., 2007; Zhang et al., 2008; Tashev et al., 2009 ). The addition of active TAT-STEP 46 (2 M) to corticostriatal slices decreased the phosphorylation level of pY 1472 of NR2B and reduced the surface expression of NR2B as determined by subcellular fractionation (66.9 Ϯ 4.5 and 69.7 Ϯ 8.9% compared with the TAT-myc-treated control; p Ͻ 0.01) (Fig. 6 A) . In contrast, TAT-STEP 33 did not significantly dephosphorylate pY 1472 and failed to reduce the surface expression of NR2B (101.7 Ϯ 8.4 and 105.0 Ϯ 9.6% of TAT-myc-treated control; p Ͼ 0.05). As a control, the surface expression of GABA A (␤2/3) receptors was not changed after treatment of slices with TAT-STEP 46 or TAT- STEP 33 (95.4 Ϯ 8.5 and 95.6 Ϯ 7.4% of TAT-myc-treated control, p Ͼ 0.05).
To confirm these results, an immunocytochemical approach was used (Fig. 6 B) . Cortical neurons (DIV 21) were treated with TAT-STEP 46 or TAT-STEP 33 (2 M) for 30 min and then stained using C-terminus anti-NR1 and anti-synapsin I antibodies. Addition of TAT-STEP 46 led to a significant decrease of surface NR1 puncta (13.4 Ϯ 1.2% compared with 18.4 Ϯ 1.8% for control; p Ͻ 0.01). However, both TAT-STEP 33 and TAT-myc failed to reduce NR1 surface expression (18.1 Ϯ 1.2 and 18.2 Ϯ 1.6%, respectively, compared with control 18.4 Ϯ 1.8%; p Ͼ 0.05). These data indicate that cleavage of STEP 61 to STEP 33 likely abrogates the ability of STEP to promote endocytosis of NMDARs.
TAT-STEP peptide prevents cleavage of endogenous STEP and is neuroprotective in cortical cultures
Because extrasynaptic activation of NMDARs induced calpaindependent cleavage of STEP 61 and was neurotoxic, we wanted to determine whether selective inhibition of STEP cleavage might be neuroprotective. To this end, a 16 aa peptide was synthesized that spanned the cleavage site and was fused with a TAT peptide. We first tested whether the TAT-STEP peptide reduced STEP cleavage in an in vitro assay with active calpain 1 (Fig. 7A ). There was a significant dose-dependent reduction of cleavage in the presence of the TAT-STEP peptide. At a concentration of 2.0 M, the peptide almost completely blocked calpainmediated cleavage of STEP (91.0 Ϯ 5.5% compared with no peptide control, 2.14 Ϯ 2.6%; p Ͻ 0.01).
The TAT-STEP peptide was then tested for its ability to block glutamatemediated STEP 33 production in neurons. Cortical neurons were incubated with different concentrations of TAT-STEP peptide for 30 min, followed by glutamate stimulation (100 M) for 1 h. Treatment with the TAT-STEP peptide resulted in a dose-dependent inhibition of glutamateinduced cleavage of STEP 61 (production of STEP 33 was 213.6 Ϯ 6.3, 172.0 Ϯ 13.2, and 149.8 Ϯ 5.1%, for 1, 2, and 4 M, respectively, compared with no peptide control, 268.8 Ϯ 14.4%; p Ͻ 0.01) (Fig. 7B) . These results indicated that the glutamate-mediated production of STEP 33 was significantly reduced by the TAT-STEP peptide.
These findings raised the possibility that the TAT-STEP peptide might be neuroprotective. To test this prediction, extrasynaptic stimulation was performed on cortical neurons preincubated with the TAT-STEP peptide or TAT-myc control (4 M). We used both LDH release and the MAP2 assay to test for cytotoxicity and cell viability after extrasynaptic stimulation. Both assays showed that the TAT-STEP peptide provided significant neuroprotection against extrasynaptic-induced cell death. Treatment with this peptide reduced LDH release (LDH release; TAT-STEP peptide pretreatment, 313.1 Ϯ 21.0% vs extrasynaptic stimulation alone, 457.6 Ϯ 21.1% of control; p Ͻ 0.01) (Fig. 7C) . As a control, calpeptin (10 M) also showed significant neuroprotection against extrasynaptic stimulation (calpeptin, 233.8 Ϯ 15.1% vs extrasynaptic stimulation alone, 457.6 Ϯ 21.1%; p Ͻ 0.01). In contrast, TAT-myc was not neuroprotective (TATmyc, 450.0 Ϯ 26.1% vs extrasynaptic stimulation alone, 457.6 Ϯ 21.1%; p Ͼ 0.05). The MAP2 assay produced similar results (Fig.  7D) . Extrasynaptic stimulation again resulted in a significant loss of MAP2 staining (60.7 Ϯ 5.8% of control, p Ͻ 0.01). However, preincubation with the TAT-STEP peptide rescued neurons from cell death (TAT-STEP peptide, 88.1 Ϯ 5.6% vs extrasynaptic stimulation alone, 60.7 Ϯ 5.8%; p Ͻ 0.01). Inhibition of calpain by calpeptin was also neuroprotective (calpeptin, 90.6 Ϯ 2.8% vs extrasynaptic stimulation alone, 60.7 Ϯ 5.8%; p Ͻ 0.01), whereas pretreatment with the TAT-myc peptide failed to protect neuronal death (TAT-myc, 64.4 Ϯ 3.3% vs extrasynaptic stimulation alone, 60.7 Ϯ 5.8%; p Ͼ 0.05).
We also visualized the protective effects of by the TAT-STEP peptide by looking at nuclear morphology during extrasynaptic stimulation. Control neurons showed normal diffuse staining of the nucleus, indicating good viability. Extrasynaptic stimulation induced significant neuronal death as identified by the morphological changes associated with apoptosis (e.g., chromatin con- Figure 5 . STEP 33 does not interact with STEP substrates. A, The substrate-trapping (C to S) mutant of STEP 46 or STEP 33 (10 g) were coupled to glutathione Sepharose beads and incubated with rat brain homogenates (100 g). Bound proteins were immunoblotted with indicated antibodies. GST protein and glutathione Sepharose beads were used as negative controls. Representative blot was shown from three independent experiments. B, p-p38 (10 ng) was incubated with STEP 33 or STEP 46 at the indicated concentrations and blotted with phospho-p38, total p38, or STEP antibodies. p-p38 levels were normalized to total p38 (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). C, GST-NR2Bc was phosphorylated by active Fyn, incubated with STEP 33 or STEP 46 at the indicated concentrations, and blotted with pNR2B (pY 1472 ), total NR2B, or STEP antibodies. pNR2B levels were normalized to total NR2B (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). densation, nuclear condensation, and segmentation) (viability, 79.4 Ϯ 4.1% of control; p Ͻ 0.05), whereas in the presence of 4 M TAT-STEP peptide, neuronal death was significantly blocked (viability, 97.8 Ϯ 3.5% compared with no peptide, 79.4 Ϯ 4.1%; p Ͻ 0.01) (Fig. 7E) .
One possibility was that the neuroprotective effects of the TAT-STEP peptide were attributable to an inhibition of NMDAR activity. We therefore determined whether the peptide reduced synaptic NMDAR function by performing whole-cell recordings of hippocampal slices. We measured the ratio of the amplitude of NMDAR-mediated EPSCs (NMDA EPSCs) to that of GABA A receptor-mediated IPSCs (GABA A IPSCs) of CA1 neurons in control (0.278 Ϯ 0.048; n ϭ 6), TAT-STEP peptide (0.369 Ϯ 0.048; n ϭ 11), and TAT-Myc (0.303 Ϯ 0.053; n ϭ 5) treated neurons. Intracellular microinjection of the TAT-STEP peptide did not alter synaptic NMDAR activity (F (2,19) ϭ 0.915; p Ͼ 0.05) (supplemental Fig. 3 , available at www. jneurosci.org as supplemental material). These results demonstrated that the neuroprotective effects of TAT-STEP peptide after extrasynaptic NMDAR stimulation were not attributable to inhibition of NMDAR activity.
In addition, we confirmed that TAT-STEP peptide did not affect ERK activation with synaptic stimulation. Cortical neurons were preincubated with TAT-STEP peptide (4 M), followed by synaptic stimulation. pERK levels were not affected by this peptide ( p Ͼ 0.05) (supplemental Fig. 4 , available at www.jneurosci.org as supplemental material).
TAT-STEP peptide is neuroprotective in the OGD model
To further assess the neuroprotective effects of blocking calpaindependent cleavage of STEP 61 , we evaluated the TAT-STEP peptide for its ability to protect corticostriatal slices from the excitotoxic effects of OGD (Zhou and Baudry, 2006) . Rat corticostriatal slices were treated with the TAT-STEP peptide, a TATmyc control, or calpeptin for 30 min before OGD, followed by reoxygenation (Fig. 8 A) . OGD alone induced a significant production of STEP 33 (Fig. 8 A, middle) (570.3 Ϯ 29.4% of control; p Ͻ 0.01). Preincubation with the TAT-STEP peptide (1 or 4 M) significantly reduced the production of STEP 33 after OGD (444.8 Ϯ 21.5 and 278.2 Ϯ 28.0% compared with no peptide control; p Ͻ 0.01). The peptide appeared selective in its inhibition, because calpain-dependent cleavage of fodrin remained unaffected even at the highest TAT-STEP concentration used. In comparison, calpeptin (10 M) reduced the OGD-induced production of STEP 33 (calpeptin, 76.8 Ϯ 5.6% vs no peptide control, 570.3 Ϯ 29.4%; p Ͻ 0.01), as well as fodrin cleavage (calpeptin, 68.6 Ϯ 9.7% vs no peptide control, 366.5 Ϯ 17.5%; p Ͻ 0.01). The TAT-myc (4 M) control had no effect on STEP 33 production after OGD (TAT-myc, 585.8 Ϯ 16.7% vs no peptide control, 570.3 Ϯ 29.4%; p Ͼ 0.05).
We also tested whether the blockade of STEP 61 cleavage might suppress the phosphorylation of p38 at Thr 180 /Tyr 182 ( Fig. 8 A,  bottom) . In agreement with previous studies (Tabakman et al., 2005; Guo and Bhat, 2007) , OGD stimulation by itself led to significant increase of phospho-p38 (499.3 Ϯ 20.4% of control; p Ͻ 0.01). Addition of TAT-STEP peptide (1 or 4 M) significantly reduced the phosphorylation of p38 (1 M, 358.4 Ϯ 13.8%; 4 M, 291.7 Ϯ 10.7% vs no peptide control, 499.3 Ϯ 20.4%; p Ͻ 0.01) after OGD. Calpeptin also significantly reduced phosphorylation of p38 (calpeptin, 222.6 Ϯ 13.6% vs no peptide control, 499.3 Ϯ 20.4%; p Ͻ 0.01). In contrast, TAT-myc had no significant effect on p38 phosphorylation (TAT-myc, 497.5 Ϯ 14.7% vs no peptide control, 499.3 Ϯ 20.4%; p Ͼ 0.05). We confirmed this finding in cortical neurons treated with glutamate. Glutamate at 100 M induced significant production of STEP 33 (314.7 Ϯ 16.1% of control; p Ͻ 0.01) and activation of p38 (378.0 Ϯ 22.4% of control; p Ͻ 0.01) (supplemental Fig. 5 , available at www. jneurosci.org as supplemental material). Preincubation with TAT-STEP peptide (4 M) significantly blocked STEP cleavage (174.5 Ϯ 11.2% compared with no peptide; 314.7 Ϯ 16.1%; p Ͻ 0.01) and p38 activation (242.9 Ϯ 9.2% compared with no peptide; 378.0 Ϯ 22.4%; p Ͻ 0.01), whereas TAT-myc peptide (4 M) failed to affect STEP cleavage and p38 activation ( p Ͼ 0.05) (supplemental Fig. 5 , available at www.jneurosci.org as supplemental material).
We then measured LDH release to determine whether the reduction of STEP 61 cleavage by TAT-STEP peptide was neuroprotective (Fig. 8 B) . OGD treatment alone induced a significant release of LDH (363.7 Ϯ 15.6% of control; p Ͻ 0.01), whereas pretreatment with the TAT-STEP peptide (4 M) significantly reduced LDH release (1 M, 267.9 Ϯ 17.4%; 4 M, 189.4 Ϯ 10.9% vs no peptide control, 363.7 Ϯ 15.6%; p Ͻ 0.01). Calpeptin reduced LDH release to a similar extent as the TAT-STEP peptide (calpeptin, 175.0 Ϯ 12.0% vs no peptide control, 363.7 Ϯ 15.6%; p Ͻ 0.01) after OGD. In contrast, TAT-myc had no significant effect on OGD-induced LDH release 362.3 Ϯ 20.6% vs no peptide control, 363.7 Ϯ 15.6%; p Ͼ 0.05).
To further examine whether reduction of STEP 61 cleavage affected p38 signaling, we examined Bax, a well established target of p38 during apoptosis (Fig. 8C) (Ghatan et al., 2000; GomezLazaro et al., 2008) . After excitotoxic stimulation, Bax translocates from the cytosol to mitochondrial fractions (Hsu et al., 1997; Cao et al., 2001 ). In agreement with previous studies, OGD alone led to the translocation of Bax to mitochondria (cytosol, Based on these results, we predicted that STEP deficiency in KO mice would affect p38 signaling. First we determined basal levels of p-p38 and p38 in STEP KO versus WT mice. We observed a significant increase of p-p38 levels in STEP KO mice (137.6 Ϯ 4.7% of control; p Ͻ 0.01), whereas total p38 levels remained constant ( p Ͼ 0.05) (supplemental Fig. 6 , available at www.jneurosci.org as supplemental material). We next investigated whether STEP KO mice would show differential excitotoxicity during OGD stimulation compared with WT littermates. Both WT and KO slices showed similar LDH production levels under basal conditions (WT, 100.4 Ϯ 1.2%; KO, 107.7 Ϯ 7.0; p Ͼ 0.05) (Fig. 8 D) . However, KO slices showed greater cell toxicity than WT slices during OGD insult (WT, 181.1 Ϯ 11.6%; KO, 259.5 Ϯ 20.6; p Ͻ 0.01). These data indicated that, in the absence of STEP, there was a significant increase in OGDmediated cell death.
Discussion
The present study was initiated in an effort to resolve an apparent paradox in the function of the STEP family of phosphatases. STEP 61 regulates the activity of both ERK1/2 and p38, proteins with very different, if not opposing, effects on cellular function. Our hypothesis was that STEP 61 would need to be tightly regulated to function both as a regulator of synaptic strengthening and of neuronal cell death. A striking finding in the present study is the differential posttranslational modification of STEP 61 depending on the type of NMDAR stimulation. Synaptic stimulation of NMDARs leads to STEP 61 ubiquitination, whereas extrasynaptic stimulation leads to STEP 61 proteolysis. In both cases, the net effect is a reduction of STEP 61 levels. We went on to confirm that synaptic stimulation leads to phosphorylation of ERK1/2 (Ivanov et al., 2006) , whereas extrasynaptic stimulation leads to phosphorylation of p38. Importantly, Figure 7 . TAT-STEP peptide is neuroprotective against glutamate excitotoxicity. A, GST-STEP 46 was digested with calpain 1 in the presence of TAT-STEP peptide at the indicated concentrations. Calpeptin (10 M) served as a control. Uncleaved STEP was normalized to no treatment control (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). B, Cortical neurons were pretreated with TAT-STEP peptide or calpeptin (10 M), followed by glutamate stimulation for 1 h. Total cell lysates were blotted with antibodies against STEP and ERK2. Production of STEP 33 was normalized to total ERK2 levels (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). C, Cell cytotoxicity was assessed by LDH release after synaptic or extrasynaptic stimulations. TAT-STEP peptide, TAT-myc, or calpeptin was preincubated as indicated before extrasynaptic stimulation (*p Ͻ 0.01, Student's t test; n ϭ 3). D, Cortical cultures were treated as in C, and cell viability was measured by MAP2 staining (*p Ͻ 0.01, Student's t test; n ϭ 3). E, Cell viability was quantified using DAPI staining. Arrows indicate injured or dead neurons, which show nuclear morphological changes (e.g., chromatin condensation, nuclear condensation, and segmentation). At least 250 randomly selected cells were counted for each stimulation (*p Ͻ 0.01, Student's t test). Scale bar, 10 m.
reducing proteolysis of STEP 61 is neuroprotective in two different models of excitotoxic cell death.
Stimulation of NMDARs can have opposing effects on neuronal survival or cell death (Hardingham and Bading, 2003) . Activation of synaptic NMDARs is coupled to CREB activation and cell survival, whereas stimulation of extrasynaptic NMDARs turns off the CREB pathway (Hardingham et al., 2002; Soriano and Hardingham, 2007; Mulholland et al., 2008) . Despite considerable progress in the analysis of different signaling pathways selectively activated by synaptic or extrasynaptic NMDARs (Hardingham et al., 2002; Zhang et al., 2007; Papadia et al., 2008; Wahl et al., 2009) , the underlying mechanisms for such marked differences in cellular responses have not been identified. The findings presented here demonstrate that the differential regulation of STEP 61 plays an important role in this process.
Calpain cleavage of STEP 61 was selectively invoked by extrasynaptic stimulation and this correlated directly with p38 activation. Calpain has been widely implicated in neurotoxicity , and calpain inhibitors have been suggested to be neuroprotective (Wells and Bihovsky, 1998) . Interestingly, calpain has also been suggested to be important for synaptic remodeling processes that underlie long-term memory (Lynch and Gleichman, 2007; . Thus, whereas excitotoxic extrasynaptic activation of calpain may have deleterious effects involving STEP 61 and p38, normal glutamatergic neurotransmission may induce calpain-dependent pathways not involving STEP 61 cleavage.
Calpain has been demonstrated to associate with Cdk5 (Kusakawa et al., 2000) , and a recent study showed that Cdk5 enhanced calpain activity , allowing us to test our model in an independent system. Given that Cdk5 increased STEP 61 proteolysis and that Cdk5 cKO mice have elevated synaptic STEP 61 with concomitant increase in pY 1472 , our results provide additional evidence that Cdk5 enhances calpain activity on its substrates that may be involved in both normal neuronal function as well as harmful pathways . Cdk5 binds NR2B and links calpain to the receptor, which, like the cofactor of Cdk5, p35, also serves as a calpain substrate, whereas NR2B serves as a substrate for both STEP 61 and calpain. Thus, one possibility is that STEP 61 is integrated into an NMDAR/calpain/Cdk5/STEP 61 signaling complex.
We found that the calpain cleavage site in STEP 61 resides within the substrate-binding domain of STEP (KIM domain). Moreover, the cleaved product (STEP 33 ) no longer interacts with four known STEP substrates despite an intact catalytic domain that retains the ability to dephosphorylate the small substrate molecule para-nitrophenylphosphate (pNPP) (Braithwaite et al., 2008) . This could be attributed to the ability of pNPP to fit within the catalytic pocket without relying on binding sites outside of the phosphatase domain to stabilize its interaction with STEP. It is possible that the STEP 33 has new substrates, similar to other calpain cleavage products of several proteins (Frangioni et al., 1993; Hou et al., 2006) . We attempted to address this issue by comparing the proteins associated with recombinant substrate-trapping variants of both STEP 46 and STEP 33 . These experiments did not reveal novel proteins binding to STEP 33 compared with STEP 46 , although more rigorous experiments may be necessary to resolve this issue.
Previously we demonstrated that STEP 61 is phosphorylated at Ser 221 by PKA and that this phosphorylation is regulated by dopamine (induces phosphorylation) and glutamate (induces dephosphorylation) (Paul et al., 2000 (Paul et al., , 2003 . Similar to the calpain cleavage site, the phosphorylation site resides within the KIM domain and has been shown to negatively affect substrate binding, thereby prolonging substrate activity (Paul et al., 2003) . Phosphorylation of various proteins by PKA and other kinases has been shown to modulate their cleavage by calpain (Wang et al., 2005; Johnson, 2006) . Thus, it is interesting to consider that STEP degradation via calpain may be regulated under physiological as well as excitotoxic conditions by dopamine signaling.
Excitotoxic stimulation of cortical cultures commonly leads to neuronal cell death. Excessive glutamate release has been implicated in a number of CNS disorders, with cell death occurring, in part, through overactivation of NMDARs (Chen et al., 2008; Schumann et al., 2008; Xu et al., 2008) . Several studies have shown that, during epileptic or ischemic insults, NMDARs are tyrosine phosphorylated by members of the Src-family kinases (SFKs), which subsequently potentiates calcium-mediated sig- Figure 8 . TAT-STEP peptide is neuroprotective in the OGD model. A, Top, Corticostriatal slices were subjected to OGD for 2 h, followed by 2 h reoxygenation in the absence or presence of TAT-STEP peptide, TAT-myc, or calpeptin. At the end of treatment, slices processed by immunoblotting with antibodies against STEP, fodrin, p-p38, or ERK2. Quantification of production of STEP 33 (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3) after normalization to total ERK2 levels (middle). Quantification of phospho-p38 is shown in the bottom (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). B, LDH release was measured at the end of treatment (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). C, Quantification of Bax in cytosol and mitochondrial fractions after normalization to tubulin (cytosol) or COX IV (mitochondria) (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 3). D, Corticostriatal slices from STEP WT or KO mice were subjected to OGD stimulation. Bar graph shows the quantitative analysis of LDH release from each group (*p Ͻ 0.01, one-way ANOVA with post hoc Tukey's test; n ϭ 10).
naling through NMDARs (Cheung et al., 2000; Takagi et al., 2003; Huo et al., 2006) . Moreover, inhibition of NMDARs or SFKs protects neurons from cell death in these models of excitotoxicity (Paul et al., 2001; Lennmyr et al., 2004; Gee et al., 2006) . We show that extrasynaptic stimulation of NMDARs promotes calpain cleavage and inactivation of STEP 61 , which normally dephosphorylates NR2B. Therefore, our findings provide an additional mechanism whereby tyrosine phosphorylation of NMDARs is enhanced after excitotoxicity.
STEP 61 normally opposes the development of synaptic strengthening by inactivating key signaling proteins in the postsynaptic terminal. STEP 61 dephosphorylates a regulatory tyrosine on ERK1/2, p38, and Fyn tyrosine kinase, thereby inactivating them (Nguyen et al., 2002; Muñoz et al., 2003; Paul et al., 2003) . In addition, STEP 61 dephosphorylates the tyr 1472 on the NR2B subunit of the NMDAR, which promotes internalization of the NMDAR complex (Snyder et al., 2005) . Tyr 1472 is also a target for Fyn phosphorylation, which leads to exocytosis of NMDAR complexes to neuronal surfaces (Dunah et al., 2004; Hallett et al., 2006) . Thus, STEP 61 promotes NMDAR internalization by both inactivating Fyn and dephosphorylating NR2B Tyr
1472 . The present study shows that STEP 33 was unable to promote endocytosis of the NMDARs (NR1/NR2B), in contrast to wildtype STEP 61 . As mentioned previously, several studies have implicated overactive NMDARs and Src-family members as a mechanism that promotes neuronal cell death. Thus, proteolytic cleavage of STEP 61 could partially explain these findings, because loss of STEP 61 activity after extrasynaptic NMDAR stimulation would increase surface expression of NMDAR complexes and increase Fyn activity. In support of our hypothesis, a previous study showed that ischemic challenge resulted in increased phosphorylation at Tyr 1472 of NR2B subunit, suggesting possible changes in the activity and/or distribution of protein tyrosine phosphatases (Besshoh et al., 2005) . Moreover, our data from the STEP KO mice support this conclusion, because there is a significant increase in OGD-mediated cell death in the absence of STEP.
To test this hypothesis, we developed a tissue diffusible interfering peptide that selectively inhibited calpain-mediated proteolysis of STEP 61 . This novel inhibitor proved neuroprotective by reducing neural death caused by excitotoxicity in cortical cultures or OGD in cortical slices. Previous studies have shown that glutamate-induced excitotoxicity relies heavily on NMDARs and involves activation of p38. Rho GTPase (Semenova et al., 2007) and nitric oxide (NO) (Bossy-Wetzel et al., 2004; Izumi et al., 2008) have been shown to be upstream of p38 signaling, which link calcium influx with the activation of the neuronal p38 and account for the subsequent cell death. p38 inhibitors (Legos et al., 2002) , inhibition of Rho (Semenova et al., 2007) , and uncoupling of neural NO synthase activation from the NMDARs (Aarts et al., 2002; Soriano et al., 2008) are effective in rescuing neurons from glutamate excitotoxicity. It will be important to determine whether STEP plays a role in modulating Rho and NO signaling.
A recent study examined the selective vulnerability of GABAergic hilar interneurons to pilocarpine-induced status epilepticus and suggested that the loss of these neurons was attributable to activation of STEP 61 and inhibition of ERK1/2 prosurvival pathways (Choi et al., 2007) . Here, we extended this previous work, which did not differentiate between synaptic and extrasynaptic stimulation of NMDARs, to support a model in which STEP 61 modulates both prosurvival and proapoptotic pathways depending on the type of input. Synaptic stimulation of NMDARs leads to ubiquitination and degradation of STEP 61 and prolongation of ERK1/2 prosurvival/synaptic plasticity pathways. Extrasynaptic stimulation leads to a selective calpain-mediated cleavage and loss of STEP 61 activity, with an upregulation of p-p38 and entry into apoptotic pathways. Although the high STEP levels in hilar interneurons seemed to predispose them to status epilepticus induced cell death, we noted in the previous study that another region expressing high levels of STEP, area CA2, was not similarly predisposed. It is possible that modulatory inputs selectively promote or dampen the cleavage of STEP and thereby alter the susceptibility of the cells of the region to excitotoxicity. In light of the current findings, it would be interesting to reexamine the pilocarpine-induced status epilepticus model and determine whether vulnerable hilar interneurons are lost attributable to STEP 61 cleavage and activation of p38 apoptotic pathways.
In conclusion, we have addressed a mechanism by which ERK1/2 and p38 are differentially regulated after glutamate stimulation of synaptic and extrasynaptic NMDARs. The tyrosine phosphatase STEP 61 plays a critical role in this process. Synaptic and extrasynaptic NMDAR stimulation promotes the degradation of STEP 61 by either ubiquitination or calpain-mediated cleavage of STEP 61 , which facilitates the activation of either ERK1/2 or p38, respectively. Because reduction of STEP 61 proteolysis proved neuroprotective to excitotoxic stimulation, our findings may have therapeutic value against excitotoxic insults within the CNS.
